More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Nanoreporter for Use with Liposomal Therapeutics



Liposomal drug delivery is an established nanomedicine platform and has gained significant clinical acceptance. However, there is high unmet need to monitor such drug delivery, release, and efficacy. This invention was developed to provide a solution for such monitoring by labeling liposomes with 89Zr for PET imaging and a near-infrared (NIR) fluorophore for optical imaging.

These bimodal labeled liposomes enable simultaneous PET and intraoperative optical imaging to non-invasively visualize the biodistribution and disease targeting of liposomal therapeutics. They match the long circulation time of liposomal therapeutics with high stability, and demonstrate an outstanding ability to target xenografts and orthotopic mouse models of breast cancer in vivo.

Moreover, these nanoparticles accumulate in areas with leaky vasculature through the enhanced permeability and retention (EPR) effect, and they can be used to detect and delineate malignant growth, inflammation, and infection in diverse disease contexts.


  • Combined advantages of PET imaging (excellent tissue penetration and high sensitivity) and optical techniques (high spatial resolution)
  • Powerful intraoperative imaging tool with wide applications in cancer, cardiovascular, and other diseases
  • Can be used as a companion imaging agent to evaluate the safety and efficacy of nanotherapeutics in preclinical and clinical settings


The global nanomedicine market was valued at over US$70 billion in 2011 and is expected to reach US$130 billion by 2016. There are more than 30 liposomal nanomedicines approved for clinical use and/or being tested in clinical trials in treating cancers, cardiovascular diseases, infections, and inflammations. This invention is of high value as a theranostic platform to enable visualization of the liposomal drug delivery and provide physicians with information for risk-benefit analysis of a given nanotherapeutic on a personalized basis.


Imaging Tool, Diagnostic


PCT Application PCT/US2015/032556 and U.S. Basic Application 14/722,425 published, both filed on May 27, 2015


Pérez-Medina C et al. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nature Communications. 2016; 7:11838 (link)

Pérez-Medina C et al. A Modular Labeling Strategy for In Vivo PET and Near-Infrared Fluorescence Imaging of Nanoparticle Tumor Targeting. J Nucl Med. 2014;55:1706-1711 (PubMed link)


Thomas Reiner, PhD, Laboratory Head, Memorial Hospital Research Laboratories, Memorial Sloan Kettering Cancer Center


Eileen Flowers, PhD
Licensing Manager
Tel: 646-888-1067

Stage of Development

Clinical development